Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
about
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic ReviewDifferential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 x Brown Norway male rats.Effects of short-term treadmill exercise training or growth hormone supplementation on diastolic function and exercise tolerance in old ratsMyocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study.Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunctionMineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.Prostasin: a possible candidate gene for human hypertensionCardiac complications of childhood myopathies.Toward a broader understanding of aldosterone in congestive heart failure.Hypertensive heart disease: effects of lifestyle modifications and antihypertensive drug treatment.Influence of Angiotensin II Subtype 2 Receptor (AT(2)R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor (AT(1)R) BlockadeEffects of spironolactone on cerebral vessel structure in rats with sustained hypertension.Vascular compliance in the cardiometabolic syndrome.Aldosterone activates endothelial exocytosis.Treatment of heart failure with preserved ejection fraction.Targeting the aldosterone pathway in cardiovascular disease.Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.Can antihypertensive medication interfere with the vicious cycle between hypertension and vascular calcification?Circulating biomarkers in patients with heart failure and preserved ejection fraction.Effects of renin-angiotensin-aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. A meta-analysis of 13 randomized controlled trials.Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment.Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension.Temporal analysis of vascular smooth muscle cell elasticity and adhesion reveals oscillation waveforms that differ with aging.Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall.Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men.Aortic stiffness: an old concept for new insights into the pathophysiology of functional mitral regurgitation.Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat.Differences in left ventricular functional adaptation to arterial stiffness and neurohormonal activation in patients with hypertension: a study with two-dimensional layer-specific speckle tracking echocardiography.Smooth Muscle Cell-Mineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging.Hypertensive Cardiovascular Risk: Pulsatile Hemodynamics, Gender, and Therapeutic Implications.Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives.Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.Differences Between Cardiac and Arterial Fibrosis and Stiffness in Aldosterone-Salt Rats: Effect of Eplerenone
P2860
Q26783958-F37C99B7-CDD1-4137-AE07-96CD99C59A23Q30451313-4518466B-AFEE-4932-A802-470938010B50Q30483339-B47F32F2-D2D8-4623-A4F8-237EC034158BQ31052911-4F9FF2CC-9369-4F62-85F4-B31E2ED18390Q33824351-4E211F59-23EE-41B6-AFFA-28B7422DA0F5Q34684861-06B371F0-C3F1-4C90-93FE-9CF13BCEFB35Q34789669-B6932F69-AC52-4A69-99F8-260D8098FAE1Q35121604-C03F5535-6F07-4265-8572-833220FC6C3EQ35580139-A1D6A45D-FCCA-4716-BE98-DA4CFB7BE6CDQ35821934-C7527614-C8EA-4375-A866-63A02C7458C7Q35830269-AE68001A-D958-4ACC-A4A6-1285B542E94BQ36999573-7CC00FAF-5F41-4C82-B9B7-F74FEADFF5D9Q37104540-3411E14D-1C52-43F3-AC85-9409F2B21D8DQ37129370-2789CDBC-9B5A-4016-A07A-ABDB96922ACFQ37848405-E612FCB5-07A5-43DE-A32E-11328DF4EA7DQ37951665-16BAE27A-F515-44F4-81E9-CB15A673177AQ38103479-D14E2ED8-7873-43DA-8115-EA3EEF83FB79Q38148988-0EA29DB3-3321-4F95-A37E-6D217A26F396Q38152289-BD8E66B0-66E3-4EF3-9916-9D63FF363492Q38566455-665A5E0F-A916-4143-9A0D-8DF6296044A5Q38593070-A12CBE67-459F-41C2-BE15-A4943047B446Q38770032-2E2A388C-87AA-4E15-AE66-717C8F660B85Q40126398-09E23724-FC14-43B2-A4A5-69624127BF26Q41986224-0D26834D-D2D9-4FF1-9B34-13A5D2F2BACBQ43093139-A65239CC-55BD-4E07-A950-3A60D64CB47FQ44956538-7BCD09C8-E5A3-4F0D-8D20-273D23ED031BQ46173870-C47476FF-2774-4049-A33B-8CAE198C8F91Q46740756-ED50FE02-6102-4575-87B7-7DBB1EFF1894Q46826285-59DC6BDF-2B57-485A-8716-E6B593DE533CQ49791319-1B1EE710-3CA4-4973-803D-74447BE9E792Q50088812-1AE9B4E0-C1CF-4ECD-BFA6-0E8792F6B374Q50143463-22ED1EF9-7652-4188-A9DE-E27962EE325DQ50899780-DF99DD3E-B43A-4F49-B8BF-21B10A422FBCQ59275526-9E183A38-3CE1-4AF3-B1C3-E874E2963C8C
P2860
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@ast
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@en
type
label
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@ast
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@en
prefLabel
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@ast
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@en
P2093
P1476
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
@en
P2093
P304
P356
10.1016/S0735-1097(00)01129-3
P407
P577
2001-02-01T00:00:00Z